-
1
-
-
79952747862
-
Alzheimer’s disease
-
Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer’s disease. Lancet. 2011;377(9770):1019–1031.
-
(2011)
Lancet
, vol.377
, Issue.9770
, pp. 1019-1031
-
-
Ballard, C.1
Gauthier, S.2
Corbett, A.3
Brayne, C.4
Aarsland, D.5
Jones, E.6
-
3
-
-
84893790299
-
Alzheimer’s disease: Charting the crossroads between neurology and psychology
-
Gilbert T, Herbst M. Alzheimer’s disease: charting the crossroads between neurology and psychology. J Neurol Neurosurg Psychiatry. 2014;85(2):133–134.
-
(2014)
J Neurol Neurosurg Psychiatry
, vol.85
, Issue.2
, pp. 133-134
-
-
Gilbert, T.1
Herbst, M.2
-
4
-
-
84897954407
-
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
-
Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol. 2014;88(4): 640–651.
-
(2014)
Biochem Pharmacol
, vol.88
, Issue.4
, pp. 640-651
-
-
Reitz, C.1
Mayeux, R.2
-
5
-
-
29144508843
-
Alzheimer’s Disease International. Global prevalence of dementia: A Delphi consensus study
-
Ferri CP, Prince M, Brayne C, et al; Alzheimer’s Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366(9503):2112–2117.
-
(2005)
Lancet
, vol.366
, Issue.9503
, pp. 2112-2117
-
-
Ferri, C.P.1
Prince, M.2
Brayne, C.3
-
6
-
-
84897481309
-
Alzheimer’s Association report
-
Fargo K, Bleiler L. Alzheimer’s Association report. Alzheimers Dement. 2014;10(2):e47–e92.
-
(2014)
Alzheimers Dement
, vol.10
, Issue.2
, pp. e47-e92
-
-
Fargo, K.1
Bleiler, L.2
-
7
-
-
84878660799
-
Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: A systematic review and analysis
-
Chan KY, Wang W, Wu JJ, et al; Global Health Epidemiology Reference Group (GHERG). Epidemiology of Alzheimer’s disease and other forms of dementia in China, 1990–2010: a systematic review and analysis. Lancet. 2013;381(9882):2016–2023.
-
(2013)
Lancet
, vol.381
, Issue.9882
, pp. 2016-2023
-
-
Chan, K.Y.1
Wang, W.2
Wu, J.J.3
-
8
-
-
84897519875
-
Deaths in the United States among persons with Alzheimer’s disease (2010–2050)
-
Weuve J, Hebert LE, Scherr PA, Evans DA. Deaths in the United States among persons with Alzheimer’s disease (2010–2050). Alzheimers Dement. 2014;10(2):e40–e46.
-
(2014)
Alzheimers Dement
, vol.10
, Issue.2
, pp. e40-e46
-
-
Weuve, J.1
Hebert, L.E.2
Scherr, P.A.3
Evans, D.A.4
-
9
-
-
84871036375
-
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010
-
Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128.
-
(2012)
Lancet
, vol.380
, Issue.9859
, pp. 2095-2128
-
-
Lozano, R.1
Naghavi, M.2
Foreman, K.3
-
10
-
-
84862253313
-
Number of people with dementia will reach 65.7 million by 2030, says report
-
Gulland A. Number of people with dementia will reach 65.7 million by 2030, says report. BMJ. 2012;344:e2604.
-
(2012)
BMJ
, vol.344
-
-
Gulland, A.1
-
11
-
-
84872119357
-
Alzheimer Disease International. The worldwide economic impact of dementia 2010
-
Wimo A, Jönsson L, Bond J, Prince M, Winblad B; Alzheimer Disease International. The worldwide economic impact of dementia 2010. Alzheimers Dement. 2013;9(1):1–11.e3.
-
(2013)
Alzheimers Dement
, vol.9
, Issue.1
, pp. 1-11.e3
-
-
Wimo, A.1
Jönsson, L.2
Bond, J.3
Prince, M.4
Winblad, B.5
-
12
-
-
77949335521
-
The worldwide societal costs of dementia: Estimates for 2009
-
Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimers Dement. 2010;6(2): 98–103.
-
(2010)
Alzheimers Dement
, vol.6
, Issue.2
, pp. 98-103
-
-
Wimo, A.1
Winblad, B.2
Jönsson, L.3
-
13
-
-
78751644048
-
Amyloid-βand Tau – a toxic pas de deux in Alzheimer’s disease
-
Ittner LM, Götz J. Amyloid-β and Tau – a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci. 2011;12(2):65–72.
-
(2011)
Nat Rev Neurosci
, vol.12
, Issue.2
, pp. 65-72
-
-
Ittner, L.M.1
Götz, J.2
-
14
-
-
77955328980
-
Fyn-Tau-amyloid: A toxic triad
-
Haass C, Mandelkow E. Fyn-Tau-amyloid: a toxic triad. Cell. 2010; 142(3):356–358.
-
(2010)
Cell
, vol.142
, Issue.3
, pp. 356-358
-
-
Haass, C.1
Mandelkow, E.2
-
15
-
-
84863337843
-
Alzheimer mechanisms and therapeutic strategies
-
Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell. 2012;148(6):1204–1222.
-
(2012)
Cell
, vol.148
, Issue.6
, pp. 1204-1222
-
-
Huang, Y.1
Mucke, L.2
-
16
-
-
84880516637
-
SnapShot: Pathobiology of Alzheimer’s disease
-
Selkoe DJ. SnapShot: pathobiology of Alzheimer’s disease. Cell. 2013; 154(2):468–468.e1.
-
(2013)
Cell
, vol.154
, Issue.2
, pp. 468-468.e1
-
-
Selkoe, D.J.1
-
17
-
-
84899019792
-
Amyloid-βand Tau: The trigger and bullet in Alzheimer disease pathogenesis
-
Bloom GS. Amyloid-β and Tau: the trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014;71(4):505–508.
-
(2014)
JAMA Neurol
, vol.71
, Issue.4
, pp. 505-508
-
-
Bloom, G.S.1
-
18
-
-
84655166490
-
Identification and biology of β-secretase
-
Kandalepas PC, Vassar R. Identification and biology of β-secretase. J Neurochem. 2012;120 Suppl 1:S55–S61.
-
(2012)
J Neurochem
, vol.120
, pp. S55-S61
-
-
Kandalepas, P.C.1
Vassar, R.2
-
19
-
-
84876014912
-
Shen Y. β-Secretase: Its biology as a therapeutic target in diseases
-
Wang H, Li R, Shen Y. β-Secretase: its biology as a therapeutic target in diseases. Trends Pharmacol Sci. 2013;34(4):215–225.
-
(2013)
Trends Pharmacol Sci
, vol.34
, Issue.4
, pp. 215-225
-
-
Wang, H.1
Li, R.2
-
20
-
-
84894090892
-
Targeting the β secretase BACE1 for Alzheimer’s disease therapy
-
Yan R, Vassar R. Targeting the β secretase BACE1 for Alzheimer’s disease therapy. Lancet Neurol. 2014;13(3):319–329.
-
(2014)
Lancet Neurol
, vol.13
, Issue.3
, pp. 319-329
-
-
Yan, R.1
Vassar, R.2
-
21
-
-
84892710970
-
Antiamyloid therapy for Alzheimer’s disease – are we on the right road?
-
Karran E, Hardy J. Antiamyloid therapy for Alzheimer’s disease – are we on the right road? N Engl J Med. 2014;370(4):377–378.
-
(2014)
N Engl J Med
, vol.370
, Issue.4
, pp. 377-378
-
-
Karran, E.1
Hardy, J.2
-
22
-
-
84884255356
-
A template for new drugs against Alzheimer’s disease
-
Aguzzi A, Gitler AD. A template for new drugs against Alzheimer’s disease. Cell. 2013;154(6):1182–1184.
-
(2013)
Cell
, vol.154
, Issue.6
, pp. 1182-1184
-
-
Aguzzi, A.1
Gitler, A.D.2
-
23
-
-
84873026509
-
Toward the treatment and prevention of Alzheimer’s disease: Rational strategies and recent progress
-
Gandy S, DeKosky ST. Toward the treatment and prevention of Alzheimer’s disease: rational strategies and recent progress. Annu Rev Med. 2013;64:367–383.
-
(2013)
Annu Rev Med
, vol.64
, pp. 367-383
-
-
Gandy, S.1
Dekosky, S.T.2
-
24
-
-
79953245971
-
Coffee and its consumption: Benefits and risks
-
Butt MS, Sultan MT. Coffee and its consumption: benefits and risks. Crit Rev Food Sci Nutr. 2011;51(4):363–373.
-
(2011)
Crit Rev Food Sci Nutr
, vol.51
, Issue.4
, pp. 363-373
-
-
Butt, M.S.1
Sultan, M.T.2
-
25
-
-
77956195598
-
Caffeine, diabetes, cognition, and dementia
-
Biessels GJ. Caffeine, diabetes, cognition, and dementia. J Alzheimers Dis. 2010;20 Suppl 1:S143–S150.
-
(2010)
J Alzheimers Dis
, vol.20
, pp. S143-S150
-
-
Biessels, G.J.1
-
27
-
-
84899452426
-
Melatonin, energy metabolism, and obesity: A review
-
Cipolla-Neto J, Amaral FG, Afeche SC, Tan DX, Reiter RJ. Melatonin, energy metabolism, and obesity: a review. J Pineal Res. 2014;56(4): 371–381.
-
(2014)
J pineal Res
, vol.56
, Issue.4
, pp. 371-381
-
-
Cipolla-Neto, J.1
Amaral, F.G.2
Afeche, S.C.3
Tan, D.X.4
Reiter, R.J.5
-
28
-
-
27644449587
-
Functional MT1 and MT2 melatonin receptors in mammals
-
Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27(2):101–110.
-
(2005)
Endocrine
, vol.27
, Issue.2
, pp. 101-110
-
-
Dubocovich, M.L.1
Markowska, M.2
-
29
-
-
0032901972
-
Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype
-
Liu RY, Zhou JN, van Heerikhuize J, Hofman MA, Swaab DF. Decreased melatonin levels in postmortem cerebrospinal fluid in relation to aging, Alzheimer’s disease, and apolipoprotein E-epsilon4/4 genotype. J Clin Endocrinol Metab. 1999;84(1):323–327.
-
(1999)
J Clin Endocrinol Metab
, vol.84
, Issue.1
, pp. 323-327
-
-
Liu, R.Y.1
Zhou, J.N.2
Van Heerikhuize, J.3
Hofman, M.A.4
Swaab, D.F.5
-
30
-
-
84890495142
-
Circadian misalignment and sleep disruption in mild cognitive impairment
-
Naismith SL, Hickie IB, Terpening Z, et al. Circadian misalignment and sleep disruption in mild cognitive impairment. J Alzheimers Dis. 2014;38(4):857–866.
-
(2014)
J Alzheimers Dis
, vol.38
, Issue.4
, pp. 857-866
-
-
Naismith, S.L.1
Hickie, I.B.2
Terpening, Z.3
-
31
-
-
84898816454
-
Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease
-
Carman AJ, Dacks PA, Lane RF, Shineman DW, Fillit HM. Current evidence for the use of coffee and caffeine to prevent age-related cognitive decline and Alzheimer’s disease. J Nutr Health Aging. 2014;18(4): 383–392.
-
(2014)
J Nutr Health Aging
, vol.18
, Issue.4
, pp. 383-392
-
-
Carman, A.J.1
Dacks, P.A.2
Lane, R.F.3
Shineman, D.W.4
Fillit, H.M.5
-
32
-
-
77956195944
-
Caffeine and coffee as therapeutics against Alzheimer’s disease
-
Arendash GW, Cao C. Caffeine and coffee as therapeutics against Alzheimer’s disease. J Alzheimers Dis. 2010;20 Suppl 1:S117–S126.
-
(2010)
J Alzheimers Dis
, vol.20
, pp. S117-S126
-
-
Arendash, G.W.1
Cao, C.2
-
33
-
-
33750984544
-
Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production
-
Arendash GW, Schleif W, Rezai-Zadeh K, et al. Caffeine protects Alzheimer’s mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience. 2006;142(4):941–952.
-
(2006)
Neuroscience
, vol.142
, Issue.4
, pp. 941-952
-
-
Arendash, G.W.1
Schleif, W.2
Rezai-Zadeh, K.3
-
34
-
-
72449208698
-
Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway
-
Canas PM, Porciúncula LO, Cunha GM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci. 2009;29(47):14741–14751.
-
(2009)
J Neurosci
, vol.29
, Issue.47
, pp. 14741-14751
-
-
Canas, P.M.1
Porciúncula, L.O.2
Cunha, G.M.3
-
35
-
-
79956272790
-
Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer’s transgenic mice and normal mice: A mechanism for electromagnetic field-induced cognitive benefit?
-
Dragicevic N, Bradshaw PC, Mamcarz M, et al. Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer’s transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit? Neuroscience. 2011; 185:135–149.
-
(2011)
Neuroscience
, vol.185
, pp. 135-149
-
-
Dragicevic, N.1
Bradshaw, P.C.2
Mamcarz, M.3
-
36
-
-
84862869928
-
High Blood caffeine levels in MCI linked to lack of progression to dementia
-
Cao C, Loewenstein DA, Lin X, et al. High Blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis. 2012;30(3): 559–572.
-
(2012)
J Alzheimers Dis
, vol.30
, Issue.3
, pp. 559-572
-
-
Cao, C.1
Loewenstein, D.A.2
Lin, X.3
-
37
-
-
79960742203
-
Caffeine synergizes with another coffee component to increase plasma GCSF: Linkage to cognitive benefits in Alzheimer’s mice
-
Cao C, Wang L, Lin X, et al. Caffeine synergizes with another coffee component to increase plasma GCSF: linkage to cognitive benefits in Alzheimer’s mice. J Alzheimers Dis. 2011;25(2):323–335.
-
(2011)
J Alzheimers Dis
, vol.25
, Issue.2
, pp. 323-335
-
-
Cao, C.1
Wang, L.2
Lin, X.3
-
38
-
-
78549290673
-
Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease
-
He H, Dong W, Huang F. Anti-amyloidogenic and anti-apoptotic role of melatonin in Alzheimer disease. Curr Neuropharmacol. 2010;8(3): 211–217.
-
(2010)
Curr Neuropharmacol
, vol.8
, Issue.3
, pp. 211-217
-
-
He, H.1
Dong, W.2
Huang, F.3
-
39
-
-
0032909996
-
Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types
-
Lahiri DK. Melatonin affects the metabolism of the beta-amyloid precursor protein in different cell types. J Pineal Res. 1999;26(3): 137–146.
-
(1999)
J Pineal Res
, vol.26
, Issue.3
, pp. 137-146
-
-
Lahiri, D.K.1
-
40
-
-
77951889295
-
The mammalian circadian timing system: Organization and coordination of central and peripheral clocks
-
Dibner C, Schibler U, Albrecht U. The mammalian circadian timing system: organization and coordination of central and peripheral clocks. Annu Rev Physiol. 2010;72:517–549.
-
(2010)
Annu Rev Physiol
, vol.72
, pp. 517-549
-
-
Dibner, C.1
Schibler, U.2
Albrecht, U.3
-
41
-
-
33847075354
-
Circadian rhythms: Mechanisms and therapeutic implications
-
Levi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications. Annu Rev Pharmacol Toxicol. 2007;47:593–628.
-
(2007)
Annu Rev Pharmacol Toxicol
, vol.47
, pp. 593-628
-
-
Levi, F.1
Schibler, U.2
-
42
-
-
0037194790
-
Coordination of circadian timing in mammals
-
Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418(6901):935–941.
-
(2002)
Nature
, vol.418
, Issue.6901
, pp. 935-941
-
-
Reppert, S.M.1
Weaver, D.R.2
-
44
-
-
84878617961
-
Chronotherapy improves blood pressure control and reduces vascular risk in CKD
-
Hermida RC, Ayala DE, Smolensky MH, et al. Chronotherapy improves blood pressure control and reduces vascular risk in CKD. Nat Rev Nephrol. 2013;9(6):358–368.
-
(2013)
Nat Rev Nephrol
, vol.9
, Issue.6
, pp. 358-368
-
-
Hermida, R.C.1
Ayala, R.2
Smolensky, M.H.3
-
45
-
-
70450239457
-
Metabolism and cancer: The circadian clock connection
-
Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9(12):886–896.
-
(2009)
Nat Rev Cancer
, vol.9
, Issue.12
, pp. 886-896
-
-
Sahar, S.1
Sassone-Corsi, P.2
-
46
-
-
84882270256
-
The circadian system in Alzheimer’s disease: Disturbances, mechanisms, and opportunities
-
Coogan AN, Schutová B, Husung S, et al. The circadian system in Alzheimer’s disease: disturbances, mechanisms, and opportunities. Biol Psychiatry. 2013;74(5):333–339.
-
(2013)
Biol Psychiatry
, vol.74
, Issue.5
, pp. 333-339
-
-
Coogan, A.N.1
Schutová, B.2
Husung, S.3
-
47
-
-
84878326836
-
Timing is important in medication administration: A timely review of chronotherapy research
-
Kaur G, Phillips C, Wong K, Saini B. Timing is important in medication administration: a timely review of chronotherapy research. Int J Clin Pharm. 2013;35(3):344–358.
-
(2013)
Int J Clin Pharm
, vol.35
, Issue.3
, pp. 344-358
-
-
Kaur, G.1
Phillips, C.2
Wong, K.3
Saini, B.4
-
48
-
-
84901417472
-
GSK-3β,a pivotal kinase in Alzheimer disease
-
Llorens-Martín M, Jurado J, Hernández F, Avila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7:46.
-
(2014)
Front Mol Neurosci
, vol.7
, pp. 46
-
-
Llorens-Martín, M.1
Jurado, J.2
Hernández, F.3
Avila, J.4
-
49
-
-
84890803688
-
Autophagy and apoptosis dysfunction in neurodegenerative disorders
-
Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol. 2014;112: 24–49.
-
(2014)
Prog Neurobiol
, vol.112
, pp. 24-49
-
-
Ghavami, S.1
Shojaei, S.2
Yeganeh, B.3
-
50
-
-
84893714992
-
Autophagy in aging and neurodegenerative diseases: Implications for pathogenesis and therapy
-
Tan CC, Yu JT, Tan MS, Jiang T, Zhu XC, Tan L. Autophagy in aging and neurodegenerative diseases: implications for pathogenesis and therapy. Neurobiol Aging. 2014;35(5):941–957.
-
(2014)
Neurobiol Aging
, vol.35
, Issue.5
, pp. 941-957
-
-
Tan, C.C.1
Yu, J.T.2
Tan, M.S.3
Jiang, T.4
Zhu, X.C.5
Tan, L.6
-
51
-
-
84927574888
-
Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies
-
Wang ZX, Sun J, Howell CE, et al. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundam Clin Pharmacol. 2014;28(5):551–582.
-
(2014)
Fundam Clin Pharmacol
, vol.28
, Issue.5
, pp. 551-582
-
-
Wang, Z.X.1
Sun, J.2
Howell, C.E.3
-
52
-
-
79952941784
-
Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study
-
Liu YH, Mo SL, Bi HC, et al. Regulation of human pregnane X receptor and its target gene cytochrome P450 3A4 by Chinese herbal compounds and a molecular docking study. Xenobiotica. 2011;41(4):259–280.
-
(2011)
Xenobiotica
, vol.41
, Issue.4
, pp. 259-280
-
-
Liu, Y.H.1
Mo, S.L.2
Bi, H.C.3
-
53
-
-
84863246281
-
Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap)
-
Mo SL, Liu WF, Chen Y, et al. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Comb Chem High Throughput Screen. 2012;15(1):36–80.
-
(2012)
Comb Chem High Throughput Screen
, vol.15
, Issue.1
, pp. 36-80
-
-
Mo, S.L.1
Liu, W.F.2
Chen, Y.3
-
54
-
-
84863549072
-
Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening
-
Mo SL, Liu WF, Li CG, et al. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening. Curr Pharm Biotechnol. 2012;13(9): 1640–1704.
-
(2012)
Curr Pharm Biotechnol
, vol.13
, Issue.9
, pp. 1640-1704
-
-
Mo, S.L.1
Liu, W.F.2
Li, C.G.3
-
55
-
-
84863049413
-
Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2
-
Yang LP, Zhou ZW, Chen XW, et al. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. Xenobiotica. 2012;42(3):238–255.
-
(2012)
Xenobiotica
, vol.42
, Issue.3
, pp. 238-255
-
-
Yang, L.P.1
Zhou, Z.W.2
Chen, X.W.3
-
56
-
-
31844439888
-
Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and Tau phosphorylation in vivo and in vitro
-
Ma QL, Lim GP, Harris-White ME, et al. Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and Tau phosphorylation in vivo and in vitro. J Neurosci Res. 2006;83(3):374–384.
-
(2006)
J Neurosci Res
, vol.83
, Issue.3
, pp. 374-384
-
-
Ma, Q.L.1
Lim, G.P.2
Harris-White, G.3
-
57
-
-
36749078121
-
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers
-
Kayed R, Head E, Sarsoza F, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener. 2007;2:18.
-
(2007)
Mol Neurodegener
, vol.2
, pp. 18
-
-
Kayed, R.1
Head, E.2
Sarsoza, F.3
-
58
-
-
84880945264
-
Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease
-
Saido TC. Metabolism of amyloid β peptide and pathogenesis of Alzheimer’s disease. Proc Jpn Acad Ser B Phys Biol Sci. 2013;89(7): 321–339.
-
(2013)
Proc Jpn Acad Ser B Phys Biol Sci
, vol.89
, Issue.7
, pp. 321-339
-
-
Saido, T.C.1
-
59
-
-
78650678688
-
Decreased clearance of CNS beta-amyloid in Alzheimer’s disease
-
Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science. 2010;330(6012):1774.
-
(2010)
Science
, vol.330
, Issue.6012
, pp. 1774
-
-
Mawuenyega, K.G.1
Sigurdson, W.2
Ovod, V.3
-
60
-
-
39749182234
-
Apoptosis: Controlled demolition at the cellular level
-
Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–241.
-
(2008)
Nat Rev Mol Cell Biol
, vol.9
, Issue.3
, pp. 231-241
-
-
Taylor, R.C.1
Cullen, S.P.2
Martin, S.J.3
-
61
-
-
84879780600
-
Autophagy: Shaping the tumor microenvironment and therapeutic response
-
Maes H, Rubio N, Garg AD, Agostinis P. Autophagy: shaping the tumor microenvironment and therapeutic response. Trends Mol Med. 2013; 19(7):428–446.
-
(2013)
Trends Mol Med
, vol.19
, Issue.7
, pp. 428-446
-
-
Maes, H.1
Rubio, N.2
Garg, A.D.3
Agostinis, P.4
-
62
-
-
0034537290
-
Autophagy as a regulated pathway of cellular degradation
-
Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science. 2000;290(5497):1717–1721.
-
(2000)
Science
, vol.290
, Issue.5497
, pp. 1717-1721
-
-
Klionsky, D.J.1
Emr, S.D.2
-
63
-
-
84890117063
-
Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage
-
Chen J, Wang L, Wu C, et al. Melatonin-enhanced autophagy protects against neural apoptosis via a mitochondrial pathway in early brain injury following a subarachnoid hemorrhage. J Pineal Res. 2014;56(1): 12–19.
-
(2014)
J Pineal Res
, vol.56
, Issue.1
, pp. 12-19
-
-
Chen, J.1
Wang, L.2
Wu, C.3
-
64
-
-
84903276737
-
Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies
-
Swomley AM, Förster S, Keeney JT, et al. Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. Biochim Biophys Acta. 2014;1842(8):1248–1257.
-
(2014)
Biochim Biophys Acta
, vol.1842
, Issue.8
, pp. 1248-1257
-
-
Swomley, A.M.1
Förster, S.2
Keeney, J.T.3
-
65
-
-
84903304059
-
Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease
-
Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer’s disease. Biochim Biophys Acta. 2014;1842(8):1240–1247.
-
(2014)
Biochim Biophys Acta
, vol.1842
, Issue.8
, pp. 1240-1247
-
-
Wang, X.1
Wang, W.2
Li, L.3
Perry, G.4
Lee, H.G.5
Zhu, X.6
-
66
-
-
58149374037
-
Antioxidant Therapy in Alzheimer’s Disease: Theory and Practice
-
Aliev G, Obrenovich ME, Reddy VP, et al. Antioxidant Therapy in Alzheimer’s Disease: Theory and Practice. Mini Rev Med Chem. 2008;8(13):1395–1406.
-
(2008)
Mini Rev Med Chem
, vol.8
, Issue.13
, pp. 1395-1406
-
-
Aliev, G.1
Obrenovich, M.E.2
Reddy, V.P.3
-
67
-
-
84878572136
-
Toward clinical application of the Keap1-Nrf2 pathway
-
Suzuki T, Motohashi H, Yamamoto M. Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol Sci. 2013;34(6):340–346.
-
(2013)
Trends Pharmacol Sci
, vol.34
, Issue.6
, pp. 340-346
-
-
Suzuki, T.1
Motohashi, H.2
Yamamoto, M.3
-
68
-
-
84867034260
-
Role of nrf2 in oxidative stress and toxicity
-
Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol. 2013;53:401–426.
-
(2013)
Annu Rev Pharmacol Toxicol
, vol.53
, pp. 401-426
-
-
Ma, Q.1
-
69
-
-
84896817308
-
Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases
-
Purro SA, Galli S, Salinas PC. Dysfunction of Wnt signaling and synaptic disassembly in neurodegenerative diseases. J Mol Cell Biol. 2014;6(1):75–80.
-
(2014)
J Mol Cell Biol
, vol.6
, Issue.1
, pp. 75-80
-
-
Purro, S.A.1
Galli, S.2
Salinas, P.C.3
-
70
-
-
84872587279
-
GSK3 and Tau: Two convergence points in Alzheimer’s disease
-
Hernandez F, Lucas JJ, Avila J. GSK3 and Tau: two convergence points in Alzheimer’s disease. J Alzheimers Dis. 2013;33 Suppl 1: S141–S144.
-
(2013)
J Alzheimers Dis
, vol.33
, pp. S141-S144
-
-
Hernandez, F.1
Lucas, J.J.2
Avila, J.3
-
71
-
-
58849083195
-
Midlife coffee and tea drinking and the risk of late-life dementia: A population-based CAIDE study
-
Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife coffee and tea drinking and the risk of late-life dementia: a population-based CAIDE study. J Alzheimers Dis. 2009;16(1): 85–91.
-
(2009)
J Alzheimers Dis
, vol.16
, Issue.1
, pp. 85-91
-
-
Eskelinen, M.H.1
Ngandu, T.2
Tuomilehto, J.3
Soininen, H.4
Kivipelto, M.5
-
72
-
-
77956203395
-
Caffeine intake and dementia: Systematic review and meta-analysis
-
Santos C, Costa J, Santos J, Vaz-Carneiro A, Lunet N. Caffeine intake and dementia: systematic review and meta-analysis. J Alzheimers Dis. 2010;20 Suppl 1:S187–S204.
-
(2010)
J Alzheimers Dis
, vol.20
, pp. S187-S204
-
-
Santos, C.1
Costa, J.2
Santos, J.3
Vaz-Carneiro, A.4
Lunet, N.5
-
73
-
-
0029742199
-
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice
-
Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 1996;274(5284):99–102.
-
(1996)
Science
, vol.274
, Issue.5284
, pp. 99-102
-
-
Hsiao, K.1
Chapman, P.2
Nilsen, S.3
-
74
-
-
44349184966
-
Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production
-
Shimizu H, Tosaki A, Kaneko K, Hisano T, Sakurai T, Nukina N. Crystal structure of an active form of BACE1, an enzyme responsible for amyloid beta protein production. Mol Cell Biol. 2008;28(11): 3663–3671.
-
(2008)
Mol cell Biol
, vol.28
, Issue.11
, pp. 3663-3671
-
-
Shimizu, H.1
Tosaki, A.2
Kaneko, K.3
Hisano, T.4
Sakurai, T.5
Nukina, N.6
-
75
-
-
1942470549
-
Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis
-
Hong L, Tang J. Flap position of free memapsin 2 (beta-secretase), a model for flap opening in aspartic protease catalysis. Biochemistry. 2004;43(16):4689–4695.
-
(2004)
Biochemistry
, vol.43
, Issue.16
, pp. 4689-4695
-
-
Hong, L.1
Tang, J.2
-
76
-
-
84879067500
-
Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease
-
Yuan J, Venkatraman S, Zheng Y, McKeever BM, Dillard LW, Singh SB. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of Alzheimer’s disease. J Med Chem. 2013; 56(11):4156–4180.
-
(2013)
J Med Chem
, vol.56
, Issue.11
, pp. 4156-4180
-
-
Yuan, J.1
Venkatraman, S.2
Zheng, Y.3
McKeever, B.M.4
Dillard, L.W.5
Singh, L.6
-
77
-
-
85027929889
-
Aβ oligomer-induced synapse degeneration in Alzheimer’s disease
-
Wilcox KC, Lacor PN, Pitt J, Klein WL. Aβ oligomer-induced synapse degeneration in Alzheimer’s disease. Cell Mol Neurobiol. 2011;31(6): 939–948.
-
(2011)
Cell Mol Neurobiol
, vol.31
, Issue.6
, pp. 939-948
-
-
Wilcox, K.C.1
Lacor, P.N.2
Pitt, J.3
Klein, W.L.4
-
78
-
-
84857642949
-
The toxic Aβ oligomer and Alzheimer’s disease: An emperor in need of clothes
-
Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012; 15(3):349–357.
-
(2012)
Nat Neurosci
, vol.15
, Issue.3
, pp. 349-357
-
-
Benilova, I.1
Karran, E.2
De Strooper, B.3
-
79
-
-
77951776829
-
Alzheimer’s disease: Strategies for disease modification
-
Citron M. Alzheimer’s disease: strategies for disease modification. Nat Rev Drug Discov. 2010;9(5):387–398.
-
(2010)
Nat Rev Drug Discov
, vol.9
, Issue.5
, pp. 387-398
-
-
Citron, M.1
-
80
-
-
84872552899
-
Synaptotoxic amyloid-β oligomers: A molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease?
-
Klein WL. Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer’s disease? J Alzheimers Dis. 2013;33 Suppl 1:S49–S65.
-
(2013)
J Alzheimers Dis
, vol.33
, pp. S49-S65
-
-
Klein, W.L.1
-
81
-
-
27644493692
-
Globular amyloid betapeptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease
-
Barghorn S, Nimmrich V, Striebinger A, et al. Globular amyloid betapeptide oligomer – a homogenous and stable neuropathological protein in Alzheimer’s disease. J Neurochem. 2005;95(3):834–847.
-
(2005)
J Neurochem
, vol.95
, Issue.3
, pp. 834-847
-
-
Barghorn, S.1
Nimmrich, V.2
Striebinger, A.3
-
82
-
-
0042838303
-
Alzheimer’s disease-affected brain: Presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss
-
Gong Y, Chang L, Viola KL, et al. Alzheimer’s disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003; 100(18):10417–10422.
-
(2003)
Proc Natl Acad Sci U S A
, vol.100
, Issue.18
, pp. 10417-10422
-
-
Gong, Y.1
Chang, L.2
Viola, K.L.3
-
83
-
-
0035846613
-
Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide
-
Poeggeler B, Miravalle L, Zagorski MG, et al. Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide. Biochemistry. 2001;40(49):14995–15001.
-
(2001)
Biochemistry
, vol.40
, Issue.49
, pp. 14995-15001
-
-
Poeggeler, B.1
Miravalle, L.2
Zagorski, M.G.3
-
84
-
-
48449102539
-
The neuroprotective role of melatonin against amyloid beta peptide injected mice
-
Masilamoni JG, Jesudason EP, Dhandayuthapani S, et al. The neuroprotective role of melatonin against amyloid beta peptide injected mice. Free Radic Res. 2008;42(7):661–673.
-
(2008)
Free Radic Res
, vol.42
, Issue.7
, pp. 661-673
-
-
Masilamoni, J.G.1
Jesudason, E.P.2
Dhandayuthapani, S.3
-
85
-
-
77954537925
-
Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline
-
Cunha RA, Agostinho PM. Chronic caffeine consumption prevents memory disturbance in different animal models of memory decline. J Alzheimers Dis. 2010;20 Suppl 1:S95–S116.
-
(2010)
J Alzheimers Dis
, vol.20
, pp. SS95-S116
-
-
Cunha, R.A.1
Agostinho, P.M.2
-
86
-
-
1842759592
-
Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression
-
Zhang YC, Wang ZF, Wang Q, Wang YP, Wang JZ. Melatonin attenuates beta-amyloid-induced inhibition of neurofilament expression. Acta Pharmacol Sin. 2004;25(4):447–451.
-
(2004)
Acta Pharmacol Sin
, vol.25
, Issue.4
, pp. 447-451
-
-
Zhang, Y.C.1
Wang, Z.F.2
Wang, Q.3
Wang, Y.P.4
Wang, J.Z.5
-
87
-
-
42149135452
-
Effect of melatonin and melatonylvalpromide on betaamyloid and neurofilaments in N2a cells
-
Wang XC, Zhang YC, Chatterjie N, Grundke-Iqbal I, Iqbal K, Wang JZ. Effect of melatonin and melatonylvalpromide on betaamyloid and neurofilaments in N2a cells. Neurochem Res. 2008; 33(6):1138–1144.
-
(2008)
Neurochem Res
, vol.33
, Issue.6
, pp. 1138-1144
-
-
Wang, X.C.1
Zhang, Y.C.2
Chatterjie, N.3
Grundke-Iqbal, I.4
Iqbal, K.5
Wang, J.Z.6
-
88
-
-
84897012511
-
From epidemiology to pathophysiology: What about caffeine in Alzheimer’s disease?
-
Flaten V, Laurent C, Coelho JE, et al. From epidemiology to pathophysiology: what about caffeine in Alzheimer’s disease? Biochem Soc Trans. 2014;42(2):587–592.
-
(2014)
Biochem Soc Trans
, vol.42
, Issue.2
, pp. 587-592
-
-
Flaten, V.1
Laurent, C.2
Coelho, J.E.3
-
89
-
-
84902082985
-
Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease-like Tau pathology
-
Laurent C, Eddarkaoui S, Derisbourg M, et al. Beneficial effects of caffeine in a transgenic model of Alzheimer’s disease-like Tau pathology. Neurobiol Aging. 2014;35(9):2079–2090.
-
(2014)
Neurobiol Aging
, vol.35
, Issue.9
, pp. 2079-2090
-
-
Laurent, C.1
Eddarkaoui, S.2
Derisbourg, M.3
-
90
-
-
84888062913
-
Epidemiology and etiology of Alzheimer’s disease: From genetic to non-genetic factors
-
Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer’s disease: from genetic to non-genetic factors. Curr Alzheimer Res. 2013;10(8):852–867.
-
(2013)
Curr Alzheimer Res
, vol.10
, Issue.8
, pp. 852-867
-
-
Jiang, T.1
Yu, J.T.2
Tian, Y.3
Tan, L.4
-
91
-
-
77953823903
-
The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells
-
Repouskou A, Sourlingas TG, Sekeri-Pataryas KE, Prombona A. The circadian expression of c-MYC is modulated by the histone deacetylase inhibitor trichostatin A in synchronized murine neuroblastoma cells. Chronobiol Int. 2010;27(4):722–741.
-
(2010)
Chronobiol Int
, vol.27
, Issue.4
, pp. 722-741
-
-
Repouskou, A.1
Sourlingas, T.G.2
Sekeri-Pataryas, K.E.3
Prombona, A.4
-
92
-
-
0041817939
-
Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia
-
Asayama K, Yamadera H, Ito T, Suzuki H, Kudo Y, Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003;70(4):334–341.
-
(2003)
J Nippon Med Sch
, vol.70
, Issue.4
, pp. 334-341
-
-
Asayama, K.1
Yamadera, H.2
Ito, T.3
Suzuki, H.4
Kudo, Y.5
Endo, S.6
-
93
-
-
53749088028
-
Nuclear factor erythroid 2-related factor 2 protects against beta amyloid
-
Kanninen K, Malm TM, Jyrkkänen HK, et al. Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci. 2008;39(3):302–313.
-
(2008)
Mol Cell Neurosci
, vol.39
, Issue.3
, pp. 302-313
-
-
Kanninen, K.1
Malm, T.M.2
Jyrkkänen, H.K.3
-
94
-
-
84897093101
-
Nrf2 reduces levels of phosphorylated Tau protein by inducing autophagy adaptor protein NDP52
-
Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, Johnson GV. Nrf2 reduces levels of phosphorylated Tau protein by inducing autophagy adaptor protein NDP52. Nat Commun. 2014;5:3496.
-
(2014)
Nat Commun
, vol.5
, pp. 3496
-
-
Jo, C.1
Gundemir, S.2
Pritchard, S.3
Jin, Y.N.4
Rahman, I.5
Johnson, G.V.6
-
95
-
-
84902578456
-
Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity
-
Kärkkäinen V, Pomeshchik Y, Savchenko E, et al. Nrf2 regulates neurogenesis and protects neural progenitor cells against Aβ toxicity. Stem Cells. 2014;32(7):1904–1916.
-
(2014)
Stem Cells
, vol.32
, Issue.7
, pp. 1904-1916
-
-
Kärkkäinen, V.1
Pomeshchik, Y.2
Savchenko, E.3
-
96
-
-
77951543964
-
Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism
-
Trinh K, Andrews L, Krause J, et al. Decaffeinated coffee and nicotine-free tobacco provide neuroprotection in Drosophila models of Parkinson’s disease through an NRF2-dependent mechanism. J Neurosci. 2010;30(16):5525–5532.
-
(2010)
J Neurosci
, vol.30
, Issue.16
, pp. 5525-5532
-
-
Trinh, K.1
Andrews, L.2
Krause, J.3
-
97
-
-
84907808578
-
Melatonin: Functions and ligands
-
Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19(9):1410–1418.
-
(2014)
Drug Discov Today
, vol.19
, Issue.9
, pp. 1410-1418
-
-
Singh, M.1
Jadhav, H.R.2
-
98
-
-
84901362118
-
Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: A review
-
Vielma JR, Bonilla E, Chacín-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: a review. Acta Trop. 2014;137: 31–38.
-
(2014)
Acta Trop
, vol.137
, pp. 31-38
-
-
Vielma, J.R.1
Bonilla, E.2
Chacín-Bonilla, L.3
Mora, M.4
Medina-Leendertz, S.5
Bravo, Y.6
-
99
-
-
84904577101
-
Ginsenoside Rd attenuates Tau protein phosphorylation via the PI3K/AKT/GSK-3β pathway after transient forebrain ischemia
-
Zhang X, Shi M, Ye R, et al. Ginsenoside Rd attenuates Tau protein phosphorylation via the PI3K/AKT/GSK-3β pathway after transient forebrain ischemia. Neurochem Res. 2014;39(7):1363–1373.
-
(2014)
Neurochem Res
, vol.39
, Issue.7
, pp. 1363-1373
-
-
Zhang, X.1
Shi, M.2
Ye, R.3
-
100
-
-
84880118137
-
Melatonin in Alzheimer’s disease
-
Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer’s disease. Int J Mol Sci. 2013;14(7):14575–14593.
-
(2013)
Int J Mol Sci
, vol.14
, Issue.7
, pp. 14575-14593
-
-
Lin, L.1
Huang, Q.X.2
Yang, S.S.3
Chu, J.4
Wang, J.Z.5
Tian, Q.6
-
101
-
-
84885947482
-
Parkinson’s disease-associated DJ-1 mutations increase abnormal phosphorylation of Tau protein through Akt/GSK-3β pathways
-
Wang Y, Liu W, He X, Zhou F. Parkinson’s disease-associated DJ-1 mutations increase abnormal phosphorylation of Tau protein through Akt/GSK-3β pathways. J Mol Neurosci. 2013;51(3):911–918.
-
(2013)
J Mol Neurosci
, vol.51
, Issue.3
, pp. 911-918
-
-
Wang, Y.1
Liu, W.2
He, X.3
Zhou, F.4
-
102
-
-
84893541699
-
The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease
-
Lynch MA. The impact of neuroimmune changes on development of amyloid pathology; relevance to Alzheimer’s disease. Immunology. 2014;141(3):292–301.
-
(2014)
Immunology
, vol.141
, Issue.3
, pp. 292-301
-
-
Lynch, M.A.1
-
103
-
-
84881481931
-
Neuronal autophagy: Self-eating or self-cannibalism in Alzheimer’s disease
-
Ułamek-Kozioł M, Furmaga-Jabłońska W, Januszewski S, et al. Neuronal autophagy: self-eating or self-cannibalism in Alzheimer’s disease. Neurochem Res. 2013;38(9):1769–1773.
-
(2013)
Neurochem Res
, vol.38
, Issue.9
, pp. 1769-1773
-
-
Ułamek-Kozioł, M.1
Furmaga-Jabłońska, W.2
Januszewski, S.3
-
104
-
-
84882254367
-
The role of autophagy in neurodegenerative disease
-
Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med. 2013;19(8):983–997.
-
(2013)
Nat Med
, vol.19
, Issue.8
, pp. 983-997
-
-
Nixon, R.A.1
-
105
-
-
84887909793
-
Autophagic/lysosomal dysfunction in Alzheimer’s disease
-
Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer’s disease. Alzheimers Res Ther. 2013;5(5):53.
-
(2013)
Alzheimers Res Ther
, vol.5
, Issue.5
, pp. 53
-
-
Orr, M.E.1
Oddo, S.2
-
106
-
-
84890082542
-
Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition
-
Vilar A, de Lemos L, Patraca I, et al. Melatonin suppresses nitric oxide production in glial cultures by pro-inflammatory cytokines through p38 MAPK inhibition. Free Radic Res. 2014;48(2):119–128.
-
(2014)
Free Radic Res
, vol.48
, Issue.2
, pp. 119-128
-
-
Vilar, A.1
De Lemos, L.2
Patraca, I.3
-
107
-
-
84890280909
-
Melatonin modulates microsomal PGE synthase 1 and NF-E2-related factor-2-regulated antioxidant enzyme expression in LPS-induced murine peritoneal macrophages
-
Aparicio-Soto M, Alarcón-de-la-Lastra C, Cárdeno A, Sánchez-Fidalgo S, Sanchez-Hidalgo M. Melatonin modulates microsomal PGE synthase 1 and NF-E2-related factor-2-regulated antioxidant enzyme expression in LPS-induced murine peritoneal macrophages. Br J Pharmacol. 2014;171(1):134–144.
-
(2014)
Br J Pharmacol
, vol.171
, Issue.1
, pp. 134-144
-
-
Aparicio-Soto, M.1
Alarcón-De-La-Lastra, C.2
Cárdeno, A.3
Sánchez-Fidalgo, S.4
Sanchez-Hidalgo, M.5
-
108
-
-
85055464242
-
Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model
-
Alamili M, Bendtzen K, Lykkesfeldt J, Rosenberg J, Gögenur I. Melatonin suppresses markers of inflammation and oxidative damage in a human daytime endotoxemia model. J Crit Care. 2014;29(1):184.e9–e184.e13.
-
(2014)
J Crit Care
, vol.29
, Issue.1
, pp. 184.e9-e184.e13
-
-
Alamili, M.1
Bendtzen, K.2
Lykkesfeldt, J.3
Rosenberg, J.4
Gögenur, I.5
-
109
-
-
84875823973
-
Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine
-
Weichelt U, Cay R, Schmitz T, et al. Prevention of hyperoxia-mediated pulmonary inflammation in neonatal rats by caffeine. Eur Respir J. 2013;41(4):966–973.
-
(2013)
Eur Respir J
, vol.41
, Issue.4
, pp. 966-973
-
-
Weichelt, U.1
Cay, R.2
Schmitz, T.3
-
110
-
-
84878349327
-
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson’s disease
-
Gołembiowska K, Wardas J, Noworyta-Sokołowska K, Kamiska K, Górska A. Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson’s disease. Neurotox Res. 2013;24(1):29–40.
-
(2013)
Neurotox Res
, vol.24
, Issue.1
, pp. 29-40
-
-
Gołembiowska, K.1
Wardas, J.2
Noworyta-Sokołowska, K.3
Kamiska, K.4
Górska, A.5
-
111
-
-
79551508637
-
Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition
-
Saiki S, Sasazawa Y, Imamichi Y, et al. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Autophagy. 2011;7(2):176–187.
-
(2011)
Autophagy
, vol.7
, Issue.2
, pp. 176-187
-
-
Saiki, S.1
Sasazawa, Y.2
Imamichi, Y.3
-
112
-
-
84896488935
-
Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice
-
Sinha RA, Farah BL, Singh BK, et al. Caffeine stimulates hepatic lipid metabolism by the autophagy-lysosomal pathway in mice. Hepatology. 2014;59(4):1366–1380.
-
(2014)
Hepatology
, vol.59
, Issue.4
, pp. 1366-1380
-
-
Sinha, R.A.1
Farah, B.L.2
Singh, B.K.3
|